The Joint Corp. (JYNT) Stock

The Joint Corp. (JYNT) is a Financials stock trading at $8.33 (as of 2026-07-24), with a market capitalization of $118.75M and a trailing P/E of 36.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

The Joint Corp. develops, owns, and operates chiropractic clinics in the United States, providing clinic management and support through direct operations and other arrangements. The company reports two segments—Corporate Clinics and Franchise Operations—and runs its clinic network through owned sites, management agreements, franchising, and regional developers.

Understand The Joint Corp.: how it makes money

The Joint Corp. develops and operates chiropractic clinics, earning money from corporate clinics (company-owned or managed) and from franchise operations (franchised clinics and related franchise revenue).

Its profit model is a hybrid, combining revenue from company-owned or managed clinics with revenue from franchised clinics, so performance depends on both clinic operations and franchise growth (licenses and clinics in operation).

Revenue by segment (latest quarter)
Corporate$0.0B
Franchise$0.0B

Business quality (Weak): Segment and operating metrics are available, but the latest reported revenue shows as 0.0B, so investors may want to verify how revenue is being rounded or classified in the latest period.

Valuation: At 41× earnings, JYNT trades 21% above the Trading average (34×). Note: one-time items can distort reported P/E.

Bull case

  • Scale is franchise-led: Clinics in operation are mostly franchised (610 franchised clinics out of 914 total clinics in operation), and franchise operations are a reportable revenue segment.
  • Demand signal is tracked: The company reports System-Wide Comparable Sales of 27.0 percent, which can help investors gauge comparable performance across its system.

Bear case

  • Thin operating cushion: Operating margin is 5.9 percent, which can leave limited room for cost pressure if clinic or franchising economics weaken.
  • Growth funnel may be a constraint: Franchise licenses sold are 13, while Franchise Licenses in Active Development are 149, so converting development into opened franchised clinics is a key execution risk.
Valuation — source: SEC EDGAR (first-party)
Price$8.33
Market Cap$118.75M
P/E Ratio36.9
EV / EBITDA113.2
Price / Book7.66
Price / Sales2.18
FCF Yield-9.8%
DCF Value (model)$2.47
DCF Upside vs Price-70.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$54.90M
Net Margin5.3%
Revenue Growth (YoY)5.2%
EPS Growth (YoY)-148.7%
FCF Growth (YoY)-95.9%
Financial Health — source: SEC EDGAR
Altman Z-Score2.20 (grey)
Valuation vs Sector & Industry
Stock P/E36.9
Sector P/E (Financials)15.4
Industry P/E (Trading)34.8
vs Sector139.9%
vs Industry6.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBandera Partners LLC ($34.85M)
Institutional Holders Tracked10
Company
SectorFinancials
IndustryTrading
CEOSanjiv Razdan
Employees443
CountryUS
IPO Date2014-11-11

Related Companies (Trading (FF48 industry); 8 closest by market cap; US-domiciled)

  • Acacia Research Corporation (ACTG)
  • ACRES Commercial Realty Corp. (ACR)
  • San Juan Basin Royalty Trust (SJT)
  • Sunrise Realty Trust, Inc. (SUNS)
  • VirnetX Holding Corp (VHC)
  • Network-1 Technologies, Inc. (NTIP)
  • Royalty Management Holding Corporation (RMCO)
  • Research Frontiers Incorporated (REFR)
JYNT earnings history · JYNT institutional & insider holders · JYNT KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.